Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIL-2 after modified radical mastectomy in breast cancer
ChiCTR-TRC-14004716Phase 4Completed
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- May 2014
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aldesleukin in breast cancer (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Percentage of regulatory T cells among CD4 T cells and Foxp3 real-time PCR. Started May 2014; status: completed.
02
Drugs
aldesleukin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-TRC-14004716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004716.